Vimarsana
Biggest News Aggregation in the World

Page 3 - Reneuron Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Reneuron Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Reneuron Group Today - Breaking & Trending Today

Portfolio Update - Vimarsana News

Portfolio Update

Octopus AIM VCT 2 plc Portfolio Update The investment portfolio of Octopus AIM VCT 2 plc as at 13 September 2023 is as follows : Portfolio companySectorBook cost Movement in valuation Fair...

Stem Cell Therapy Market: Resilient Shine with Projected 16.7% CAGR Growth from 2022 to 2032, Unlock - Vimarsana News

Stem Cell Therapy Market: Resilient Shine with Projected 16.7% CAGR Growth from 2022 to 2032, Unlock

The Stem Cell Therapies Market is anticipated to increase from US$ 187 million in 2021 to US$ 401 million by 2026, at a CAGR of 16.7%, by 2032.The COVID-19 pandemic has caused severe impacts on the global economy at various levels and which can be seen on the Healthcare industry as well. The thriving market of healt...

ReNeuron highlights exosome platform R&D progress - Vimarsana News

ReNeuron highlights exosome platform R&D progress

ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) said it has taken an important step forward with plans to differentiate its exosome platform by generating in vivo...

ReNeuron reaches exosome research milestone - Vimarsana News

ReNeuron reaches exosome research milestone

UK-based biotechnology company ReNeuron Group, which specialises in stem cell-derived exosome technologies, announced significant advancements in the field of exosome research on Monday.

ReNeuron makes progress on exosome delivery platform - Vimarsana News

ReNeuron makes progress on exosome delivery platform

ReNeuron Group PLC - Brigend, Wales-based stem cell and exosomes technology company - Generates in vivo data to exemplify cellular and tissue targeting capabilities of exosomes, produced from its...